在中国慢性乙型肝炎患者中，无论先前是否接受过核苷（酸）类似物治疗，替诺福韦酯单药治疗均有效。

TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in China.

作者信息

Huang Mingxing, Lin Guoli, Shi Hong, Wu Yuankai, Jie Yusheng, Zhu Zhe, Chong Yutian

机构信息

Department of Infectious Diseases, The Fifth Affiliated Hospital of Sun Yat-sen University (SYSU), Zhuhai, Guangdong, China.

Department of Infectious Diseases, The Third Affiliated Hospital, Sun Yat-sen University (SYSU), Guangzhou, Guangdong, China.

出版信息

Biomed Res Int. 2017;2017:2463197. doi: 10.1155/2017/2463197. Epub 2017 Apr 12.

DOI:10.1155/2017/2463197

PMID:28656138

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5471559/

Abstract

BACKGROUND/AIMS: Many patients had to transfer to tenofovir disoproxil fumarate (TDF) if there is other nucleos(t)ide analogue (NA) resistance. We aimed to investigate antiviral effects of TDF monotherapy between NA-naive and NA-experienced chronic hepatitis B (CHB) patients in China.

METHODS

A total of 102 NA-naive and NA-experienced CHB patients with TDF monotherapy (300 mg/day) were retrospectively analyzed for useful parameters up to 72 weeks.

RESULTS

There were 36 and 66 patients with matched HBV DNA baseline level in NA-naïve and NA-experienced group, respectively. There were no significant differences between NA-naïve and NA-experienced groups in HBV DNA levels (all > 0.05) and HBV DNA undetectable rates (all > 0.05) at all time points. At the end of follow-up, HBV DNA undetectable rates in NA-naïve and NA-experienced group were 96.2% (25/26) and 91.8% (45/49), respectively ( = 0.476). Baseline HBV DNA level was the only independent predictor for HBV DNA negative time ( = 0.018). In addition, 27.8% (5/18) and 11.4% (4/35) achieved HBeAg seroconversion at the end of the follow-up, respectively ( = 0.133).

CONCLUSIONS

TDF monotherapy was effective regardless of prior NA experienced. Baseline HBV DNA was a key predictive factor for HBV DNA negative time in TDF monotherapy.

摘要

背景/目的：如果存在其他核苷（酸）类似物（NA）耐药，许多患者不得不改用富马酸替诺福韦二吡呋酯（TDF）。我们旨在研究在中国初治和经治慢性乙型肝炎（CHB）患者中TDF单药治疗的抗病毒效果。

方法

回顾性分析了总共102例接受TDF单药治疗（300毫克/天）的初治和经治CHB患者长达72周的有效参数。

结果

初治组和经治组分别有36例和66例患者的HBV DNA基线水平匹配。在所有时间点，初治组和经治组在HBV DNA水平（均>0.05）和HBV DNA不可测率（均>0.05）方面均无显著差异。随访结束时，初治组和经治组的HBV DNA不可测率分别为96.2%（25/26）和91.8%（45/49）（P = 0.476）。基线HBV DNA水平是HBV DNA转阴时间的唯一独立预测因素（P = 0.018）。此外，随访结束时分别有27.8%（5/18）和11.4%（4/35）实现了HBeAg血清学转换（P = 0.133）。